PainChek Ltd
ASX:PCK
PainChek Ltd
ASX:PCK
Price:
0.03 AUD
Market Closed
Updated:
May 19, 2024
P/B
Price to Book Value
Price to Book Value
39.2
Current
11.1
Median
2.3
Industry
Higher
than median
Higher
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=39.2
Market Cap
/
49.1m
Book Value of Equity
1.3m
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| AU |
|
PainChek Ltd
ASX:PCK
|
49.1m AUD | 39.2 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
33.9B USD | 7.3 | |
| US |
|
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 7.1 | |
| US |
|
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 2.7 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
12.2B AUD | 76.7 | |
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY | 3.3 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
5.2B USD | 5.8 | |
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
4.6B USD | 7.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
45.6B SEK | 32.9 | |
| US |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
2.8B USD | 4.4 | |
| US |
|
Vocera Communications Inc
NYSE:VCRA
|
2.8B USD | 17 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
